IMUNON, Inc. showcased new Phase 2 clinical data for its DNA-based immunotherapy IMNN-001 at the AACR D3 conference, highlighting its potential to improve survival in advanced ovarian cancer. IMNN-001 delivers interleukin-12 locally to tumors, enhancing immune response with a favorable safety profile. Phase 2 results showed a median overall survival increase of 14.7 months compared to chemotherapy alone. The company is advancing its Phase 3 OVATION-3 trial to confirm these benefits and aims for regulatory approval if successful.
Fabrinet is set to report strong Q3 2026 earnings with revenue forecasted at about $1.276 billion, a 41% increase year-over-year, driven by demand in Telecom and Data Center sectors. Earnings per share are expected to rise 45% to $3.81, reflecting ro...
Jernigan Capital, a REIT specializing in financing self-storage facilities, saw its stock rise over 11% to $24.00, reaching a new 52-week high. Analysts have a consensus "Moderate Buy" rating with an average 12-month price target of $27.50, suggestin...
CrowdStrike, a leading cybersecurity firm, has seen its stock price increase by 85% year-to-date, reaching a market cap over $220 billion. Investment firm Cowen & Co. reiterated a "Buy" rating and raised the price target to $235, citing strong financ...
Metallus is rated a buy due to strong Q2 demand, 12% year-over-year revenue growth, higher shipments, and improved net sales per ton. Aerospace and defense shipments surged, positioning the company for a potential re-rating if it reaches a $250 milli...
Prediction market data shows traders assign a 51% probability that Tesla and SpaceX will announce a merger by May 1, 2027, with the likelihood increasing as the date approaches. The two Elon Musk-led companies already collaborate in technology and ma...
